“My talk [highlights] unmet research needs that need to be addressed to further improve the adjuvant treatment landscape for our patients,” said Pavlos Msaouel, MD, PhD.
In this video, Pavlos Msaouel, MD, PhD, discusses the key points of his presentation, “The future of adjuvant therapy for high-risk non-metastatic RCC,” presented during the 2021 Society of Urologic Oncology Annual Meeting. Msaouel is an assistant professor in the department of genitourinary medical oncology of the division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.